Medical Pharmacology: Chapter 36 — Antiviral Pharmacology -- Module 8

Chapter 36 — Antiviral Pharmacology — Module 8 — Antiviral Resistance Principles

1. [CASE 1 — QUESTION 1] A 60-year-old kidney transplant recipient maintained on tacrolimus and mycophenolate develops cytomegalovirus (CMV) viremia and is started on appropriately dosed valganciclovir. After two weeks of confirmed adherence and adequate dosing, the plasma CMV viral load has not declined by at least 1 log10. Genotyping returns an isolated UL97 (CMV phosphotransferase) mutation at codon 595 with a wild-type UL54 (CMV DNA polymerase) gene. Which interpretation of this genotype is correct, and what does it imply for therapy?

A) The UL97 mutation abolishes activity of ganciclovir, foscarnet, and cidofovir simultaneously, leaving no nucleoside or pyrophosphate-analog option.
B) The isolated UL97 mutation confers ganciclovir resistance by impairing ganciclovir monophosphorylation, while foscarnet and cidofovir remain active because neither requires UL97 for activation, and maribavir also remains an option.
C) The UL97 mutation indicates the failure is pharmacokinetic rather than virologic, so no drug change is warranted.
D) The UL97 mutation confers resistance only to foscarnet, so ganciclovir should be continued at the same dose.
E) The UL97 mutation restores full ganciclovir susceptibility, so the lack of response must be due to an unrelated infection.

ANSWER: B

Rationale:

Option B is correct. UL97 phosphorylates ganciclovir to its monophosphate; an isolated UL97 mutation impairs that activation step, conferring ganciclovir resistance while leaving foscarnet and cidofovir fully active because neither depends on UL97. Maribavir, which inhibits UL97 at a site distinct from ganciclovir, also remains an option against many UL97 mutations.

Option A: Option A is incorrect. An isolated UL97 mutation does not abolish foscarnet and cidofovir activity; both remain active.
Option C: Option C is incorrect. A defined UL97 resistance mutation is virologic resistance; adherence and dosing were already confirmed adequate.
Option D: Option D is incorrect. UL97 mutations confer ganciclovir resistance, not isolated foscarnet resistance, so continuing ganciclovir unchanged is inappropriate.
Option E: Option E is incorrect. The UL97 mutation reduces ganciclovir activation rather than restoring susceptibility; the nonresponse is explained by resistance.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. The patient is switched to foscarnet and initially responds, but after several weeks of continued immunosuppression the viral load rises again. Repeat genotyping now shows the original UL97 mutation plus a new UL54 (CMV DNA polymerase) mutation. What is the significance of the emergent UL54 mutation?

A) A UL54 mutation always restores ganciclovir susceptibility, so the patient can simply resume valganciclovir.
B) A UL54 mutation affects only UL97-dependent activation and therefore has no effect on foscarnet or cidofovir.
C) A UL54 mutation guarantees pan-susceptibility to all agents because polymerase mutations reduce viral fitness to zero.
D) A UL54 polymerase mutation may confer cross-resistance to foscarnet, cidofovir, or both depending on its location within the polymerase domain, and the combined UL97 plus UL54 genotype is the most clinically challenging resistance scenario.
E) A UL54 mutation is irrelevant because resistance is determined solely by UL97 in all cases.

ANSWER: D

Rationale:

Option D is correct. UL54 encodes the CMV DNA polymerase, the direct target of foscarnet and cidofovir. An emergent UL54 mutation can confer cross-resistance to foscarnet, cidofovir, or both depending on the affected domain, and combined UL97 plus UL54 mutations represent the most difficult resistance scenario to treat.

Option A: Option A is incorrect. UL54 mutations add resistance burden and do not restore ganciclovir susceptibility.
Option B: Option B is incorrect. UL54 mutations act at the polymerase and can directly compromise foscarnet and cidofovir, which target that enzyme.
Option C: Option C is incorrect. UL54 mutations confer additional resistance, not pan-susceptibility, and do not abolish viral fitness.
Option E: Option E is incorrect. UL54 is highly relevant; resistance is not determined by UL97 alone, particularly once a polymerase mutation emerges.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. The transplant team asks why this particular patient developed not one but two sequential CMV resistance mutations over the course of therapy. Which explanation best identifies the underlying driver?

A) Profound pharmacologic immunosuppression prevents immune clearance of residual virus, so prolonged antiviral therapy applies sustained drug selection pressure without the immune co-factor that normally eliminates low-level replication, favoring sequential emergence of resistant variants.
B) Transplant recipients are inherently unable to mount any antiviral drug response, so resistance is unrelated to immune status.
C) The resistance was transmitted from the donor organ and was fully present before any antiviral exposure.
D) Calcineurin inhibitors are directly mutagenic to CMV, independently generating resistance mutations.
E) Resistance emerged because the antiviral doses were excessive, and lowering the dose would have prevented it.

ANSWER: A

Rationale:

Option A is correct. The unifying driver of antiviral resistance emergence is the combination of an immunocompromised host who cannot clear virus immunologically and prolonged drug selection pressure. Without immune elimination of residual replication, resistant variants are repeatedly selected, which is why heavily immunosuppressed transplant recipients on extended therapy are at highest risk and can develop sequential mutations.

Option B: Option B is incorrect. Resistance is closely tied to immune status; the deficiency of immune clearance is precisely what drives it.
Option C: Option C is incorrect. The mutations emerged sequentially during therapy, consistent with treatment-emergent selection, not pre-existing transmitted resistance.
Option D: Option D is incorrect. Calcineurin inhibitors suppress host immunity; they are not direct mutagens of CMV.
Option E: Option E is incorrect. Resistance here arose from sustained selection in an immunodeficient host, not from excessive dosing; subtherapeutic exposure, not overdosing, more commonly promotes resistance.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. Maribavir is considered as part of the management strategy. Which statement correctly describes maribavir's mechanism and its relevance to this patient's resistance pattern?

A) Maribavir is a nucleoside analog that, like ganciclovir, requires UL97-mediated phosphorylation, so UL97 mutations abolish its activity.
B) Maribavir inhibits the UL54 DNA polymerase directly and is therefore the preferred agent precisely when a UL54 mutation is present.
C) Maribavir is a benzimidazole riboside that inhibits the UL97 kinase through a binding site distinct from ganciclovir's, so it retains activity against many UL97 resistance mutations and is approved for refractory or resistant CMV in transplant recipients.
D) Maribavir works by chelating magnesium at the integrase active site, identical to the HIV integrase inhibitors.
E) Maribavir requires viral thymidine kinase for activation, so it is inactive against any phosphotransferase-mutant CMV.

ANSWER: C

Rationale:

Option C is correct. Maribavir is a benzimidazole riboside that inhibits the UL97 kinase at a binding site distinct from ganciclovir's. Because it does not depend on UL97-mediated phosphorylation and engages a different site, it retains activity against many UL97 resistance mutations (notably at codons such as 460 and 595) and is FDA-approved for refractory or resistant CMV in transplant recipients.

Option A: Option A is incorrect. Maribavir is not a UL97-activated nucleoside analog; it inhibits the UL97 kinase itself at a distinct site.
Option B: Option B is incorrect. Maribavir targets UL97, not the UL54 polymerase, so it is not the agent of choice specifically for a UL54 mutation.
Option D: Option D is incorrect. Maribavir does not act at integrase; magnesium chelation at integrase describes HIV integrase strand transfer inhibitors.
Option E: Option E is incorrect. Maribavir does not require viral thymidine kinase; that activation pathway pertains to acyclovir against herpes simplex virus.

5. [CASE 2 — QUESTION 1] A 44-year-old man with HIV has been on tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TDF/FTC/EFV) for three years with a documented history of intermittent adherence. His plasma HIV ribonucleic acid (RNA), previously undetectable, is now confirmed at 22,000 copies per milliliter. A resistance genotype is correctly obtained while he remains on the failing regimen. Which resistance pattern is most consistent with this clinical picture?

A) Integrase mutations Q148H and N155H, the expected consequence of efavirenz pressure.
B) Hepatitis B virus rtM204V/I, selected by emtricitabine within HIV reverse transcriptase.
C) M184V from emtricitabine pressure together with a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) mutation such as K103N from efavirenz pressure, reflecting the low-barrier components of the regimen.
D) Primary protease inhibitor mutations only, since TDF/FTC/EFV exerts pressure mainly on protease.
E) No mutations at all, because tenofovir-containing regimens never select resistance.

ANSWER: C

Rationale:

Option C is correct. The low genetic-barrier components of TDF/FTC/EFV are emtricitabine and efavirenz. With intermittent adherence, emtricitabine pressure readily selects the M184V discrimination mutation, and efavirenz pressure readily selects a first-generation NNRTI mutation such as K103N, making this the expected genotype on the failing regimen.

Option A: Option A is incorrect. Q148H and N155H are integrase mutations; the regimen contains no integrase inhibitor and exerts no integrase pressure.
Option B: Option B is incorrect. rtM204V/I is the hepatitis B virus lamivudine-resistance mutation, not an HIV mutation selected by emtricitabine in HIV reverse transcriptase.
Option D: Option D is incorrect. The regimen contains no protease inhibitor, so no protease pressure is applied.
Option E: Option E is incorrect. Resistance does emerge on tenofovir-containing regimens, particularly via the low-barrier emtricitabine and efavirenz components.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. His genotype confirms M184V and K103N, and review of records shows two primary protease inhibitor mutations from a remote prior regimen but no documented integrase mutations. You aim to build a salvage regimen with at least two fully active agents. Which combination best applies salvage principles?

A) Continue efavirenz and add a second non-nucleoside reverse transcriptase inhibitor, since stacking NNRTIs overcomes K103N.
B) Recycle emtricitabine and tenofovir alone, relying on the low fitness cost of M184V to maintain suppression.
C) Use a first-generation integrase inhibitor as the sole active drug, since integrase inhibitors are immune to all prior resistance.
D) Prescribe lamivudine monotherapy, because M184V reduces viral fitness enough to control replication.
E) Combine a second-generation integrase inhibitor (dolutegravir, counted fully active given no documented integrase mutations) with ritonavir-boosted darunavir (which retains substantial activity with only two primary protease mutations), achieving an optimized regimen with at least two fully active agents.

ANSWER: E

Rationale:

Option E is correct. With no documented integrase mutations, a second-generation INSTI such as dolutegravir counts as fully active because its high genetic barrier requires accumulation of multiple mutations. Boosted darunavir retains substantial activity unless three or more primary protease mutations are present, and only two are documented here. Together they provide at least two fully active agents, consistent with salvage regimen principles.

Option A: Option A is incorrect. K103N confers high-level resistance across first-generation NNRTIs, and stacking NNRTIs does not overcome it.
Option B: Option B is incorrect. With M184V and K103N present, recycling emtricitabine and tenofovir does not supply two fully active agents; low fitness cost of M184V does not equate to suppression.
Option C: Option C is incorrect. A single integrase inhibitor is insufficient (one agent), and integrase inhibitors are not immune to resistance.
Option D: Option D is incorrect. Lamivudine monotherapy will not suppress a resistant virus; reduced fitness from M184V is not adequate control.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. A colleague proposes reintroducing efavirenz in a future regimen, arguing that if a repeat genotype taken after stopping efavirenz no longer shows K103N, the drug class can be safely reused. How should this reasoning be evaluated?

A) The colleague is correct; once K103N is no longer detected, efavirenz susceptibility has fully returned and the class can be reused freely.
B) The reasoning is flawed: K103N, once selected, persists as archived resistance that can fall below the detection threshold off-drug but re-emerges rapidly under renewed NNRTI pressure, so efavirenz should be treated as compromised regardless of a later wild-type genotype.
C) The reasoning is flawed only because efavirenz is too toxic, not for any resistance-related reason.
D) The colleague is correct, because NNRTI mutations are erased from the viral genome within weeks of stopping the drug.
E) The question cannot be resolved, because archived resistance is a theoretical construct with no clinical relevance.

ANSWER: B

Rationale:

Option B is correct. Resistance mutations such as K103N persist as archived resistance in proviral DNA and minority populations even when they drop below the detection threshold of standard genotyping after the selecting drug is withdrawn. Reintroducing the NNRTI class would rapidly re-select the mutation, so efavirenz must be regarded as compromised despite a later apparently wild-type genotype.

Option A: Option A is incorrect. Non-detection off-drug does not mean susceptibility has returned; the mutation is archived.
Option C: Option C is incorrect. The decisive problem is archived resistance, not drug toxicity.
Option D: Option D is incorrect. NNRTI mutations are not erased from the genome; they persist and can re-emerge.
Option E: Option E is incorrect. Archived resistance is clinically real and directly informs regimen selection.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. Over subsequent years he accumulates an increasingly complex resistance profile, and standard genotypic interpretation rules begin to give ambiguous predictions because of multiple interacting mutations. Which testing approach is most appropriate to resolve his net drug susceptibility?

A) Phenotypic resistance testing, because directly measuring the virus's replication across a range of drug concentrations reports the net fold-change in inhibitory concentration and resolves the combined effect of multiple interacting mutations that genotypic rules cannot reliably predict.
B) Standard Sanger genotyping repeated several times, since interacting mutations are always fully captured by genotypic interpretation rules.
C) Co-receptor tropism testing, because tropism alone determines susceptibility to every antiretroviral class.
D) Plasma drug-level monitoring, because pharmacokinetic data substitute for resistance interpretation in complex cases.
E) No further testing, because resistance in heavily treatment-experienced patients cannot be characterized by any method.

ANSWER: A

Rationale:

Option A is correct. Phenotypic testing directly measures viral replication across drug concentrations and reports a net fold-change in IC50 against clinical cutoffs. It is especially valuable when multiple interacting mutations produce complex patterns that genotypic interpretation rules struggle to predict, which is the classic indication in heavily treatment-experienced patients despite its longer turnaround and higher cost.

Option B: Option B is incorrect. Genotypic interpretation can be precisely the ambiguous element when many mutations interact, which is the scenario described.
Option C: Option C is incorrect. Tropism testing governs maraviroc use only, not susceptibility to all classes.
Option D: Option D is incorrect. Drug-level monitoring assesses exposure and adherence, not the resistance phenotype.
Option E: Option E is incorrect. Resistance in treatment-experienced patients is characterizable, and phenotyping is well suited to complex cases.

9. [CASE 3 — QUESTION 1] A 50-year-old man with chronic hepatitis B virus (HBV) infection has been maintained on lamivudine monotherapy for four years, with previously suppressed HBV deoxyribonucleic acid (DNA). Over the past three months his HBV DNA has risen by roughly 3 log10 and his alanine aminotransferase (ALT) has flared to several times the upper limit of normal. Adherence is confirmed. Which interpretation best explains this development?

A) This represents spontaneous hepatitis B surface antigen seroconversion, a favorable event requiring no change in therapy.
B) This reflects lamivudine hepatotoxicity, and the rising HBV DNA is an incidental laboratory finding.
C) This indicates acute hepatitis A superinfection unrelated to HBV therapy.
D) This is virologic breakthrough from lamivudine resistance, most likely the rtM204V/I mutation (methionine-to-valine/isoleucine at reverse transcriptase position 204), commonly with the compensatory rtL180M, consistent with the high resistance rate of long-term lamivudine monotherapy.
E) This is expected during the first weeks of lamivudine therapy and does not indicate resistance.

ANSWER: D

Rationale:

Option D is correct. Rising HBV DNA accompanied by an ALT flare after years of lamivudine monotherapy is classic virologic breakthrough from lamivudine resistance, most often the rtM204V/I mutation, frequently with compensatory rtL180M. This matches the well-documented high cumulative resistance of long-term lamivudine monotherapy.

Option A: Option A is incorrect. Surface antigen seroconversion is accompanied by declining, not rising, viral markers.
Option B: Option B is incorrect. The rising HBV DNA is the central finding of breakthrough, not an incidental result, and lamivudine hepatotoxicity does not explain rising viral load.
Option C: Option C is incorrect. The picture is HBV virologic breakthrough on a failing low-barrier drug, not hepatitis A superinfection.
Option E: Option E is incorrect. This occurs after four years of therapy, not in the first weeks, and does indicate resistance.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. Genotyping confirms rtM204V/I plus rtL180M. Which change in antiviral therapy is most appropriate?

A) Increase the lamivudine dose, since rtM204V/I resistance is dose-dependent and reversible with escalation.
B) Add telbivudine to lamivudine, since combining two L-nucleoside analogs overcomes rtM204V/I.
C) Switch to adefovir monotherapy, the highest-barrier agent available for HBV.
D) Continue lamivudine and simply monitor, since breakthrough often resolves spontaneously.
E) Switch to tenofovir (TDF or TAF), which has the highest resistance barrier of any approved HBV agent with no confirmed clinical resistance after more than 15 years of use.

ANSWER: E

Rationale:

Option E is correct. Tenofovir (disoproxil fumarate or alafenamide) has the highest genetic barrier of any approved HBV agent and no confirmed clinical resistance after more than 15 years of use, making it the appropriate switch for a lamivudine-resistant virus carrying rtM204V/I plus rtL180M.

Option A: Option A is incorrect. rtM204V/I is not overcome by dose escalation, which contradicts the resistance mechanism.
Option B: Option B is incorrect. Telbivudine is an L-nucleoside analog cross-affected by rtM204V/I, so combining it with lamivudine does not overcome resistance.
Option C: Option C is incorrect. Adefovir is a low-barrier agent (about 30% resistance by year five as monotherapy), not the highest-barrier choice.
Option D: Option D is incorrect. Virologic breakthrough with an ALT flare does not resolve spontaneously and requires switching to an effective high-barrier agent.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. A trainee asks why entecavir, a recognized high-barrier HBV agent, is not the preferred switch for this particular patient. What is the best explanation?

A) Entecavir is a low-barrier agent in all patients and is never appropriate for chronic HBV.
B) Entecavir requires viral thymidine kinase for activation, which this patient lacks.
C) Entecavir resistance requires rtM204V/I plus rtL180M plus one additional mutation; because this patient already carries rtM204V/I and rtL180M from lamivudine resistance, only one further mutation is needed, substantially elevating entecavir resistance risk and making tenofovir the preferred choice.
D) Entecavir and lamivudine share no resistance pathway, so prior lamivudine resistance has no effect on entecavir.
E) Entecavir is contraindicated because it cannot be used in any patient with an ALT flare.

ANSWER: C

Rationale:

Option C is correct. De novo entecavir resistance requires three changes — rtM204V/I plus rtL180M plus one additional mutation. A lamivudine-resistant virus already carries rtM204V/I and rtL180M, so only one more mutation is needed, sharply raising entecavir resistance risk in this setting. Tenofovir, unaffected by these mutations, is therefore preferred.

Option A: Option A is incorrect. Entecavir is genuinely high-barrier in treatment-naive patients; it is the prior lamivudine resistance that lowers its barrier here.
Option B: Option B is incorrect. Entecavir is not a thymidine-kinase-dependent agent; that mechanism applies to acyclovir against herpes simplex virus.
Option D: Option D is incorrect. Entecavir and lamivudine share the rtM204V/I and rtL180M pathway, which is exactly why prior lamivudine resistance matters.
Option E: Option E is incorrect. An ALT flare does not contraindicate entecavir; the issue is the shared resistance pathway, not the flare.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. Routine testing now reveals he is also HIV-positive and antiretroviral-naive. How does this co-infection influence selection of his HBV therapy?

A) HBV therapy should be stopped entirely so that HIV can be treated first with an unrelated regimen.
B) A tenofovir-based regimen is advantageous because tenofovir is active against both HBV and HIV, so a tenofovir-containing combination antiretroviral regimen treats both viruses simultaneously; HBV agents should not be used as the only active drug against HIV.
C) Lamivudine monotherapy should be resumed, since it adequately covers both HBV and HIV by itself.
D) The two infections are pharmacologically unrelated, so the HBV and HIV regimens share no agents.
E) Entecavir monotherapy is preferred because it fully suppresses HIV as well as HBV.

ANSWER: B

Rationale:

Option B is correct. Tenofovir is active against both HBV and HIV, so a tenofovir-containing combination antiretroviral regimen treats both viruses at once. Importantly, agents with anti-HBV and anti-HIV activity must be used within a fully suppressive HIV regimen, not as a single active drug against HIV, to avoid selecting HIV resistance.

Option A: Option A is incorrect. HBV therapy should not be stopped; co-infection is managed with a regimen active against both viruses concurrently.
Option C: Option C is incorrect. Lamivudine monotherapy is inadequate for HIV (and this virus is already lamivudine-resistant for HBV).
Option D: Option D is incorrect. The infections share agents such as tenofovir, which is precisely why co-infection guides drug choice.
Option E: Option E is incorrect. Entecavir has limited anti-HIV activity and can select HIV resistance if used without a full antiretroviral regimen; it does not fully suppress HIV.

13. [CASE 4 — QUESTION 1] A 38-year-old man with advanced acquired immunodeficiency syndrome (AIDS) and a cluster of differentiation 4 (CD4) count of 22 cells per microliter has progressively enlarging, non-healing anogenital ulcers despite 14 days of adequately dosed intravenous acyclovir with confirmed adherence. A lesion swab confirms herpes simplex virus (HSV), and thymidine kinase (TK) gene sequencing reveals a TK-null phenotype. What is the most appropriate next step?

A) Switch to intravenous foscarnet, because the TK-null phenotype eliminates activation of all TK-dependent agents, and foscarnet inhibits the viral DNA polymerase without requiring viral TK.
B) Increase the acyclovir dose, since a TK-null phenotype is overcome by higher drug exposure.
C) Switch to oral valacyclovir, since its higher bioavailability bypasses the TK requirement.
D) Add famciclovir to acyclovir, since two TK-dependent agents together restore activity against TK-null virus.
E) Discontinue antiviral therapy and manage with topical care alone.

ANSWER: A

Rationale:

Option A is correct. A confirmed TK-null phenotype abolishes activation of all thymidine-kinase-dependent agents (acyclovir, valacyclovir, penciclovir, famciclovir). Foscarnet directly inhibits the viral DNA polymerase at the pyrophosphate-binding site and does not require viral TK, so it is the appropriate pivot.

Option B: Option B is incorrect. A TK-null phenotype cannot be overcome by dose escalation because the activating enzyme is absent.
Option C: Option C is incorrect. Valacyclovir is a prodrug of acyclovir and still depends on viral TK, so improved bioavailability does not help.
Option D: Option D is incorrect. Famciclovir (via penciclovir) is also TK-dependent, so combining two TK-dependent agents does not restore activity.
Option E: Option E is incorrect. Stopping antiviral therapy abandons treatable resistant infection when an effective TK-independent agent is available.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. After an initial response to foscarnet, the ulcers begin to progress again, and repeat sequencing now identifies a viral DNA polymerase (UL30) mutation in addition to the TK-null phenotype. Which agent is the most appropriate next option, and what is the underlying reasoning?

A) Resume acyclovir, since the polymerase mutation restores thymidine kinase function.
B) Increase the foscarnet dose indefinitely, since polymerase mutations are always overcome by higher foscarnet exposure.
C) Switch back to valacyclovir, since polymerase mutations do not affect TK-dependent activation.
D) Switch to cidofovir, because cidofovir is converted to its active diphosphate by cellular enzymes independently of viral thymidine kinase and can retain activity when a DNA polymerase mutation has compromised foscarnet, recognizing that polymerase mutations may confer variable cross-resistance depending on location.
E) Stop all antiviral therapy, since a double-mutant virus is untreatable by any agent.

ANSWER: D

Rationale:

Option D is correct. A DNA polymerase mutation can confer foscarnet cross-resistance depending on its location. Cidofovir diphosphate is generated by cellular enzymes independently of viral thymidine kinase, so cidofovir is the appropriate option for foscarnet-refractory or TK-null/polymerase double-mutant HSV, with the recognition that polymerase mutations can produce variable cross-resistance.

Option A: Option A is incorrect. A polymerase mutation does not restore thymidine kinase function; the TK-null phenotype persists, so acyclovir remains inactive.
Option B: Option B is incorrect. Once a polymerase mutation compromises foscarnet, escalating foscarnet does not reliably overcome resistance.
Option C: Option C is incorrect. Valacyclovir depends on viral thymidine kinase, which is absent in this TK-null virus.
Option E: Option E is incorrect. Cidofovir remains a treatment option; the virus is not untreatable.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. A junior clinician proposes that any time an immunocompromised patient's herpesvirus lesions fail to improve on antiviral therapy, the team should immediately assume drug resistance and switch agents. What general principle should temper this approach?

A) Resistance and inadequate drug exposure present so differently that they are never confused, so immediate empiric switching is always safe.
B) Antiviral failure in an immunocompromised patient is always resistance, so switching agents without further evaluation is correct.
C) Drug levels are irrelevant to herpesvirus treatment outcomes, so only genotyping should guide management.
D) Resistance testing should be deferred until the patient is no longer immunocompromised, since testing is uninformative during immunosuppression.
E) Because inadequate drug exposure (poor absorption, dosing errors, drug interactions) and true resistance can produce clinically identical pictures but require different responses, drug levels and adherence should be assessed first to exclude pharmacokinetic failure before attributing nonresponse to resistance.

ANSWER: E

Rationale:

Option E is correct. A unifying principle across herpesviruses is that pharmacokinetic failure and true resistance look clinically identical yet demand different management. Confirming adequate drug exposure and adherence first — before invoking resistance — prevents premature, potentially more toxic drug switches when the real problem is underdosing or poor absorption.

Option A: Option A is incorrect. The two failure modes look identical and are easily confused, so immediate switching is not uniformly safe.
Option B: Option B is incorrect. Failure should not be assumed to be resistance without excluding pharmacokinetic causes.
Option C: Option C is incorrect. Drug levels are directly relevant; assessing exposure is part of the first step.
Option D: Option D is incorrect. Resistance testing is informative during immunosuppression and should not be deferred.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. Reflecting on this case, the team discusses how the resistance principles illustrated here would inform preparedness for a future emerging viral pathogen. Which strategy best generalizes the lesson to pandemic antiviral planning?

A) Deploy a single most-potent antiviral as monotherapy across the population to simplify distribution during a surge.
B) Defer resistance surveillance until resistance becomes widespread, then introduce combination therapy reactively.
C) Combine mechanistically distinct agents that target separate viral proteins so the virus must acquire simultaneous resistance at multiple targets, prioritize such combinations for immunocompromised and high-risk patients, and maintain a mechanistically diverse stockpile.
D) Rely on dose escalation of one agent to outpace resistance, avoiding the complexity of combinations.
E) Treat only immunocompetent patients, since they are the principal source of resistance emergence.

ANSWER: C

Rationale:

Option C is correct. The case illustrates that resistance is contained by raising the genetic barrier. Generalized to pandemic preparedness, this means combining mechanistically distinct agents against separate viral targets so simultaneous multi-target resistance is required, prioritizing such combinations for the immunocompromised and high-risk patients who drive resistance emergence, and maintaining a mechanistically diverse stockpile to avoid single-point-of-failure resistance.

Option A: Option A is incorrect. Population-wide monotherapy is the classic low-barrier failure mode that predictably selects resistance.
Option B: Option B is incorrect. Surveillance should precede widespread deployment, not wait until resistance is established.
Option D: Option D is incorrect. Dose escalation of one agent does not raise the genetic barrier the way mechanistically distinct combination therapy does.
Option E: Option E is incorrect. Immunocompromised patients, not immunocompetent ones, are the principal source of resistance and warrant the most intensive attention.